Surabhi Dangi-Garimella, PhD

Following the approval of daratumumab earlier this month, multiple myeloma patients now have another opportunity to combat the disease: elotuzumab.

Relaxed direct-to-consumer advertising restrictions for drugs by the FDA in 1997 has precipitated an increase in prescription drug utilization, not just among Medicare enrollees, but also among non-elderly users.

The American College of Physicians has published a paper in the Annals of Internal Medicine that advices clinicians to prescribe generic drugs whenever possible.

The approval follows 5 months after Bristol-Myers Squibb submitted phase 3 results of the Checkmate-066 trial for FDA review.

Two months after being granted a Breakthrough Therapy designation by the FDA for metastatic renal cell carcinoma (mRCC), nivolumab was today approved by regulators for treating mRCC patients who have failed a certain type of prior therapy.

A state-led program, initiated in 2003, has nearly doubled screening colonoscopy rates in New York City and also eliminated racial and ethnic disparities in the process.

A pharmacist who engages in formulary decisions, a medical director for population management for a private health exchange, and an innovations leader at a pharmacy benefit manager, took to the podium at the Patient-Centered Oncology Care meeting on November 20, 2015, to discuss cost-saving strategies in oncology and whether benefit managers can play a role in reining-in some of these costs.

At the Patient-Centered Oncology Care 2015 meeting, held November 19-20, 2015, in Baltimore, Maryland, keynote speaker Julie M. Vose, MD, MBA, FASCO, president of the American Society of Clinical Oncology provided perspectives on the challenges faced by oncologists as the healthcare system transitions to define and incorporate value in the care delivered.

Eligibility for prescription coverage and family income significantly influenced women's decisions to continue hormonal therapy and prevent recurrence of breast cancer, the authors found.

The American Society of Clinical Oncology has made public its detailed guidance to CMS, supporting implementation of physician-focused and other alternative payment models under MACRA.

This is the company's third biosimilar Biologics License Application in the United States.

The drug is estimated to cost close to $13,000 per month.

It is time to regulate laboratory-developed tests that cost Medicare $9.7 billion in the year 2012 alone.

The drug was approved based on results of 2 open-label studies that showed reduction in tumor burden of patients who had previously received multiple lines of therapy.

When to screen and how to screen remain controversial issues in prostate cancer.

According to the CDC, while smoking rates are seeing a steady decline, rates for uninsured and adults on Medicaid are more than twice those for adults with private health insurance.

A study in The European Journal of Public Health finds conversation on preventive vaccination against HPV can motivate participation in preventive screening for cervical cancer.

A retrospective study conducted at the Mayo Clinic found improved OS and PFS in ovarian cancer patients with a history of oral contraceptive use.

A forced closing of Health Republic Insurance of New York has left many in need of immediate coverage.

Published in JAMA Oncology, the trial found an association between loss of heterozygosity and cancer-free survival in patients who had been diagnosed with oral premalignant lesions.

Heterogeneity in quality of care and cancer patient survival based on insurance coverage are the highlight of a report by researchers at the Institute for Population Health Improvement at the University of California Davis.

Treatment of a recurrent brain tumor harboring a BRAF mutation with an inhibitor approved for melanoma resulted in dramatic tumor shrinkage.

The FDA's meta-analyses, following results of the DAPT trial in 2014, have found no association between treatment with the blood thinner clopidogrel (Plavix) and increased incidence of, or death due to, cancer.

From CMS to private health plans, professional healthcare organizations to patients and advocacy groups, the discussion nowadays seems to end up with value.

A blood test that can detect mutations in the androgen receptor can predict response to abiraterone in prostate cancer.

New research, published in JAMA Oncology, presents evidence of how the use of disease-specific hashtags on Twitter can help those with common interests collectively share information.

Published in the journal Cancer, the study evaluated the short-term and long-term costs of treating patients with low-risk prostate cancer across the entire care spectrum.

According to a study published in The International Journal of Cancer, tubal ligation can reduce the risk of serous, endometrioid, and clear cell ovarian carcinoma.

A new research study published in the Journal of Dermatology has found that propranolol, a commonly used antihypertensive agent, could substantially reduce proliferation of angiosarcoma.

After melanoma and non-small cell lung cancer, the FDA has granted Breakthrough Therapy status to pembrolizumab in advanced colorectal cancer patients with mismatched repair deficiency.